UPLIZNA

Indicated For

NMOSD, IgG4-RD, gMG

About This Medication

# Amgen By Your Side Patient Guide: How to Get UPLIZNA® (inebilizumab-cdon) at Low or No Cost UPLIZNA® (inebilizumab-cdon) is an infusion medication manufactured by Amgen for adults with specific rare conditions, and the **Amgen By Your Side** program offers financial support like copay assistance to make it more affordable.[1][4][5] This guide explains eligibility, application steps, and support options in simple terms to help you access treatment. ## About UPLIZNA® and Who It's For **UPLIZNA® (inebilizumab-cdon)** is a prescription medicine given by infusion to treat adults (18 years and older) with: - Neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-aquaporin-4 (AQP4) antibodies. - Immunoglobulin G4-related disease (IgG4-RD). - Generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.[1][3][5][7] It works by targeting certain immune cells to reduce attacks on the body in these conditions. UPLIZNA is **not approved for children**, and it's administered in a healthcare setting, often with pre-medications like corticosteroids, antihistamines, and antipyretics to prevent infusion reactions.[2][3] **Key warnings**: Do not use if you have active hepatitis B, untreated tuberculosis, or had a life-threatening reaction to UPLIZNA. It may increase infection risk, especially with other immune-suppressing drugs. Tell your doctor about infections, hepatitis history, or breastfeeding plans. Common side effects include urinary tract infections, joint pain, and infusion reactions like headache or nausea. Monitor immunoglobulin levels during treatment.[1][3][5] Always discuss risks with your healthcare provider (HCP) and review the full Prescribing Information. ## Who Qualifies for Amgen By Your Side Support Amgen By Your Side is the main support program for UPLIZNA patients, providing **non-medical help** like financial assistance, education on billing, and access coordination.[2][5][8] It's open to U.S. and Puerto Rico residents aged 18+ prescribed UPLIZNA—no enrollment coverage requirement or needs-based testing for copay help.[4] **Primary offering: Copay Assistance Program** – Eligible commercially insured patients can get **$0 copay** on UPLIZNA, reducing out-of-pocket costs significantly.[1][4] This is **not income-based**; it's for those with commercial (private) insurance. Medicare, Medicaid, or uninsured patients may have other options through patient advocacy groups or bridge programs—call for details.[1][6] **Special: Medically Urgent Bridge Program** – For NMOSD patients (AQP4-IgG+) needing urgent therapy while insurance is pursued. Requires HCP attestation of medical urgency (e.g., recent relapses), enrollment, and pursuit of coverage. Provides expedited access.[6] ## Income Eligibility Breakdown The copay program has **no specific income thresholds**—eligibility focuses on commercial insurance, U.S./Puerto Rico residency, and age 18+.[4] It's not needs-based, making it accessible without financial proof. For other potential aid (e.g., free drug for uninsured), contact Amgen By Your Side, as details vary. | Household Size | Income Limit | FPL % | Notes | |---------------|--------------|-------|-------| | Individual | None specified | N/A | Commercial insurance required for copay; no income test.[4] | | Couple | None specified | N/A | Same as above. | | Family of 3 | None specified | N/A | Call 1-844-469-4297 for uninsured options.[6] | | Family of 4+ | None specified | N/A | Residency in US/PR required. | If uninsured or government-insured, advocacy partners may help—program connects you.[1] ## Insurance Requirements - **Commercial/Private Insurance**: Eligible for $0 copay via enrollment.[4] - **Medicare/Medicaid**: Copay program not applicable; explore bridge or advocacy support.[1][6] - **Uninsured**: May qualify for bridge (urgent cases) or other Amgen resources—HCP must pursue coverage.[6] No prior authorization details listed, but Amgen By Your Side offers billing education and Patient Access Liaisons.[7] ## Step-by-Step Application Process 1. **Get Prescribed**: Confirm UPLIZNA is right for you with your HCP.[5] 2. **Enroll in Amgen By Your Side**: Visit the patient portal or have your HCP download the enrollment form from UPLIZNAhcp.com.[4][6] 3. **Complete Form**: Patient or HCP fills it out. Include insurance details for copay help.[4] 4. **Submit**: HCP faxes to 833-329-8477, emails to UPLIZNAABYS@amgen.com, or submits online. Patients call 833-842-8477 (or 1-844-469-4297) for help.[4][6] 5. **Approval**: Program reviews quickly, especially for urgent cases.[6] 6. **Start Treatment**: Copay card or support activates; infusions at approved sites. Your dedicated case manager helps throughout.[7] ## Timeline and Delivery - **Processing**: Not specified, but bridge program is expedited for urgent needs. Call for status.[6] - **Delivery**: UPLIZNA is infused in a clinic/hospital—not shipped home. Program coordinates site access and billing.[2] - **Refills**: Ongoing support via enrollment; re-enroll or reauthorize as needed (details via phone).[7] Expect support from enrollment through continued treatment. ## Alternatives if Denied or Ineligible - **Appeal**: Work with HCP and Amgen team to pursue insurance coverage.[6] - **Bridge Program**: For urgent NMOSD cases during coverage pursuit.[6] - **Patient Advocacy**: Program links to organizations for additional aid.[1] - **Other Amgen Programs**: Like SupportPlus for broader help.[9] - **Generic/Biosimilars**: None listed for UPLIZNA.[ ] Contact Amgen By Your Side immediately for personalized options. ## Disclaimer This guide is for informational purposes based on available program details as of general knowledge. Eligibility, benefits, and terms can change—always verify with Amgen By Your Side at 1-844-469-4297 or your HCP. Not a substitute for medical advice. Report side effects to FDA at 1-800-FDA-1088. Amgen does not guarantee coverage or assistance.

Program information last verified: March 30, 2026